These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31711127)

  • 1. In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles.
    Ricke-Hoch M; Hoes MF; Pfeffer TJ; Schlothauer S; Nonhoff J; Haidari S; Bomer N; Scherr M; Stapel B; Stelling E; Kiyan Y; Falk C; Haghikia A; Binah O; Arany Z; Thum T; Bauersachs J; van der Meer P; Hilfiker-Kleiner D
    Cardiovasc Res; 2020 Sep; 116(11):1875-1886. PubMed ID: 31711127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy.
    Pfeffer TJ; Mueller JH; Haebel L; Erschow S; Yalman KC; Talbot SR; Koenig T; Berliner D; Zwadlo C; Scherr M; Hilfiker-Kleiner D; Bauersachs J; Ricke-Hoch M
    ESC Heart Fail; 2023 Feb; 10(1):465-477. PubMed ID: 36300679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.
    Nonhoff J; Ricke-Hoch M; Mueller M; Stapel B; Pfeffer T; Kasten M; Scherr M; von Kaisenberg C; Bauersachs J; Haghikia A; Hilfiker-Kleiner D
    Cardiovasc Res; 2017 May; 113(6):598-608. PubMed ID: 28453725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy.
    Feyen E; Ricke-Hoch M; Van Fraeyenhove J; Vermeulen Z; Scherr M; Dugaucquier L; Viereck J; Bruyns T; Thum T; Segers VFM; Hilfiker-Kleiner D; De Keulenaer GW
    Circ Heart Fail; 2021 Jul; 14(7):e006898. PubMed ID: 34247489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress.
    Ricke-Hoch M; Bultmann I; Stapel B; Condorelli G; Rinas U; Sliwa K; Scherr M; Hilfiker-Kleiner D
    Cardiovasc Res; 2014 Mar; 101(4):587-96. PubMed ID: 24448315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.
    Halkein J; Tabruyn SP; Ricke-Hoch M; Haghikia A; Nguyen NQ; Scherr M; Castermans K; Malvaux L; Lambert V; Thiry M; Sliwa K; Noel A; Martial JA; Hilfiker-Kleiner D; Struman I
    J Clin Invest; 2013 May; 123(5):2143-54. PubMed ID: 23619365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripartum cardiomyopathy: basic mechanisms and hope for new therapies.
    Ricke-Hoch M; Pfeffer TJ; Hilfiker-Kleiner D
    Cardiovasc Res; 2020 Mar; 116(3):520-531. PubMed ID: 31605117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy.
    Stapel B; Kohlhaas M; Ricke-Hoch M; Haghikia A; Erschow S; Knuuti J; Silvola JM; Roivainen A; Saraste A; Nickel AG; Saar JA; Sieve I; Pietzsch S; Müller M; Bogeski I; Kappl R; Jauhiainen M; Thackeray JT; Scherr M; Bengel FM; Hagl C; Tudorache I; Bauersachs J; Maack C; Hilfiker-Kleiner D
    Eur Heart J; 2017 Feb; 38(5):349-361. PubMed ID: 28201733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic Imbalance and Residual Myocardial Injury in Recovered Peripartum Cardiomyopathy Patients.
    Goland S; Weinstein JM; Zalik A; Kuperstein R; Zilberman L; Shimoni S; Arad M; Ben Gal T; George J
    Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy.
    Haghikia A; Podewski E; Libhaber E; Labidi S; Fischer D; Roentgen P; Tsikas D; Jordan J; Lichtinghagen R; von Kaisenberg CS; Struman I; Bovy N; Sliwa K; Bauersachs J; Hilfiker-Kleiner D
    Basic Res Cardiol; 2013 Jul; 108(4):366. PubMed ID: 23812247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study.
    Damp J; Givertz MM; Semigran M; Alharethi R; Ewald G; Felker GM; Bozkurt B; Boehmer J; Haythe J; Skopicki H; Hanley-Yanez K; Pisarcik J; Halder I; Gorcsan J; Rana S; Arany Z; Fett JD; McNamara DM;
    JACC Heart Fail; 2016 May; 4(5):380-8. PubMed ID: 26970832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers in Peripartum Cardiomyopathy-What We Know and What Is Still to Be Found.
    Kryczka KE; Demkow M; Dzielińska Z
    Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perhexiline treatment improves toxic effects of β-adrenergic receptor stimulation in experimental peripartum cardiomyopathy.
    Pfeffer TJ; List M; Müller JH; Scherr M; Bauersachs J; Hilfiker-Kleiner D; Ricke-Hoch M
    ESC Heart Fail; 2021 Aug; 8(4):3375-3381. PubMed ID: 34002539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers.
    Azibani F; Pfeffer TJ; Ricke-Hoch M; Dowling W; Pietzsch S; Briton O; Baard J; Abou Moulig V; König T; Berliner D; Libhaber E; Schlothauer S; Anthony J; Lichtinghagen R; Bauersachs J; Sliwa K; Hilfiker-Kleiner D
    ESC Heart Fail; 2020 Apr; 7(2):512-522. PubMed ID: 32064780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating T-Cell Subsets, Monocytes, and Natural Killer Cells in Peripartum Cardiomyopathy: Results From the Multicenter IPAC Study.
    McTiernan CF; Morel P; Cooper LT; Rajagopalan N; Thohan V; Zucker M; Boehmer J; Bozkurt B; Mather P; Thornton J; Ghali JK; Hanley-Yanez K; Fett J; Halder I; McNamara DM;
    J Card Fail; 2018 Jan; 24(1):33-42. PubMed ID: 29079307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of NT-proBNP for myocardial recovery in peripartum cardiomyopathy (PPCM).
    Hoevelmann J; Muller E; Azibani F; Kraus S; Cirota J; Briton O; Ntsekhe M; Ntusi NAB; Sliwa K; Viljoen CA
    Clin Res Cardiol; 2021 Aug; 110(8):1259-1269. PubMed ID: 33555408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomic Profiling in Patients With Peripartum Cardiomyopathy: A Biomarker Study of the ESC EORP PPCM Registry.
    Kodogo V; Viljoen C; Hoevelmann J; Chakafana G; Tromp J; Farhan HA; Goland S; van der Meer P; Karaye K; Kryczka K; Hilfiker-Kleiner D; Jackson A; Mebazaa A; Böhm M; Pieske B; Bauersachs J; Bell L; Sliwa K;
    JACC Heart Fail; 2023 Dec; 11(12):1708-1725. PubMed ID: 37804308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.
    Bauersachs J; König T; van der Meer P; Petrie MC; Hilfiker-Kleiner D; Mbakwem A; Hamdan R; Jackson AM; Forsyth P; de Boer RA; Mueller C; Lyon AR; Lund LH; Piepoli MF; Heymans S; Chioncel O; Anker SD; Ponikowski P; Seferovic PM; Johnson MR; Mebazaa A; Sliwa K
    Eur J Heart Fail; 2019 Jul; 21(7):827-843. PubMed ID: 31243866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripartum women with dyspnea in the emergency department: Is it peripartum cardiomyopathy?
    Wang WW; Wang Y
    Medicine (Baltimore); 2018 Aug; 97(31):e11516. PubMed ID: 30075517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of Early Diagnosis in Peripartum Cardiomyopathy.
    Lewey J; Levine LD; Elovitz MA; Irizarry OC; Arany Z
    Hypertension; 2020 Jan; 75(1):91-97. PubMed ID: 31707840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.